SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137683544> ?p ?o ?g. }

Showing items 1 to 100 of ±134 with 100 items per page.

W3137683544 endingPage "1826" @default.
W3137683544 startingPage "1816" @default.
W3137683544 abstract "Isatuximab (Isa), an anti-CD38 monoclonal antibody, and carfilzomib (K), a next-generation proteasome inhibitor (PI), both have potent single-agent activity in relapsed and refractory multiple myeloma (RRMM).This phase 1b study evaluated the combination of Isa and K in 33 patients with RRMM. Isa was administered by intravenous infusion in 3 dosing cohorts: dose level 1 (Isa at 10 mg/kg biweekly), dose level 2 (DL2; Isa at 10 mg/kg weekly for 4 doses and then biweekly), and dose level 3 (Isa at 20 mg/kg weekly for 4 doses and then biweekly) and all patients received K (20 mg/m2 intravenously for cycle 1, days 1 and 2, and then 27 mg/m2 for all subsequent doses). A standard 3+3 dose-escalation design was used, no dose-limiting toxicity was observed, and the maximum tolerated dose was not reached. An expansion cohort of 18 patients was enrolled at DL2 to further evaluate safety and efficacy. Responses were assessed with the International Myeloma Working Group response criteria, and patients continued treatment until disease progression or unacceptable toxicity.With a median follow-up of 26.7 months, in this heavily pretreated population with a median of 3 prior lines (refractory to PIs and immunomodulatory drugs, 76%; refractory to K, 27%), the overall response rate was 70% (stringent complete response/complete response, 4; very good partial response, 8; partial response, 11). The median progression-free survival was 10.1 months, and the 2-year survival probability was 76%. The most common treatment-related adverse events (grade 2 or higher) were anemia, leukopenia, neutropenia, thrombocytopenia, hypertension, and infection. Infusion reactions were common (55%) but did not limit dosing.Treatment with Isa plus K was well tolerated with no unexpected toxicity. The combination was effective despite the enrollment of heavily pretreated patients with RRMM.This phase 1b study was designed to assess the safety, pharmacokinetics, and preliminary efficacy of isatuximab and carfilzomib in patients with relapsed and refractory multiple myeloma. Thirty-three patients were treated: 15 in dose escalation and 18 in dose expansion. Patients received an average of 10 cycles. The treatment was safe and effective. No unexpected toxicity or drug-drug interactions were noted. Seventy percent of the subjects responded to therapy, and the progression-free survival was 10.1 months." @default.
W3137683544 created "2021-03-29" @default.
W3137683544 creator A5004466299 @default.
W3137683544 creator A5006038485 @default.
W3137683544 creator A5006108161 @default.
W3137683544 creator A5011954777 @default.
W3137683544 creator A5014158343 @default.
W3137683544 creator A5023752321 @default.
W3137683544 creator A5028046297 @default.
W3137683544 creator A5030703994 @default.
W3137683544 creator A5030726651 @default.
W3137683544 creator A5043259076 @default.
W3137683544 creator A5051483089 @default.
W3137683544 creator A5053904944 @default.
W3137683544 creator A5077359554 @default.
W3137683544 creator A5082709335 @default.
W3137683544 creator A5083373965 @default.
W3137683544 creator A5083444057 @default.
W3137683544 creator A5091675809 @default.
W3137683544 date "2021-03-18" @default.
W3137683544 modified "2023-10-17" @default.
W3137683544 title "Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma" @default.
W3137683544 cites W2010232494 @default.
W3137683544 cites W2072259475 @default.
W3137683544 cites W2096735689 @default.
W3137683544 cites W2130794506 @default.
W3137683544 cites W2182681254 @default.
W3137683544 cites W2201190784 @default.
W3137683544 cites W2229483068 @default.
W3137683544 cites W2486629951 @default.
W3137683544 cites W2512106959 @default.
W3137683544 cites W2528329272 @default.
W3137683544 cites W2596793886 @default.
W3137683544 cites W2606797830 @default.
W3137683544 cites W2612430336 @default.
W3137683544 cites W2625253716 @default.
W3137683544 cites W2688500010 @default.
W3137683544 cites W2891882983 @default.
W3137683544 cites W2899675310 @default.
W3137683544 cites W2927473213 @default.
W3137683544 cites W2945434115 @default.
W3137683544 cites W2947874495 @default.
W3137683544 cites W2950944873 @default.
W3137683544 cites W2970009779 @default.
W3137683544 cites W2988984460 @default.
W3137683544 cites W2990147138 @default.
W3137683544 cites W2996752315 @default.
W3137683544 cites W3043410628 @default.
W3137683544 cites W3106161534 @default.
W3137683544 doi "https://doi.org/10.1002/cncr.33448" @default.
W3137683544 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8252002" @default.
W3137683544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33735504" @default.
W3137683544 hasPublicationYear "2021" @default.
W3137683544 type Work @default.
W3137683544 sameAs 3137683544 @default.
W3137683544 citedByCount "6" @default.
W3137683544 countsByYear W31376835442021 @default.
W3137683544 countsByYear W31376835442022 @default.
W3137683544 countsByYear W31376835442023 @default.
W3137683544 crossrefType "journal-article" @default.
W3137683544 hasAuthorship W3137683544A5004466299 @default.
W3137683544 hasAuthorship W3137683544A5006038485 @default.
W3137683544 hasAuthorship W3137683544A5006108161 @default.
W3137683544 hasAuthorship W3137683544A5011954777 @default.
W3137683544 hasAuthorship W3137683544A5014158343 @default.
W3137683544 hasAuthorship W3137683544A5023752321 @default.
W3137683544 hasAuthorship W3137683544A5028046297 @default.
W3137683544 hasAuthorship W3137683544A5030703994 @default.
W3137683544 hasAuthorship W3137683544A5030726651 @default.
W3137683544 hasAuthorship W3137683544A5043259076 @default.
W3137683544 hasAuthorship W3137683544A5051483089 @default.
W3137683544 hasAuthorship W3137683544A5053904944 @default.
W3137683544 hasAuthorship W3137683544A5077359554 @default.
W3137683544 hasAuthorship W3137683544A5082709335 @default.
W3137683544 hasAuthorship W3137683544A5083373965 @default.
W3137683544 hasAuthorship W3137683544A5083444057 @default.
W3137683544 hasAuthorship W3137683544A5091675809 @default.
W3137683544 hasBestOaLocation W31376835441 @default.
W3137683544 hasConcept C121332964 @default.
W3137683544 hasConcept C126322002 @default.
W3137683544 hasConcept C142424586 @default.
W3137683544 hasConcept C143998085 @default.
W3137683544 hasConcept C197934379 @default.
W3137683544 hasConcept C2776364478 @default.
W3137683544 hasConcept C2778367456 @default.
W3137683544 hasConcept C2780108899 @default.
W3137683544 hasConcept C2908647359 @default.
W3137683544 hasConcept C29730261 @default.
W3137683544 hasConcept C71924100 @default.
W3137683544 hasConcept C87355193 @default.
W3137683544 hasConcept C90924648 @default.
W3137683544 hasConcept C98274493 @default.
W3137683544 hasConcept C99454951 @default.
W3137683544 hasConceptScore W3137683544C121332964 @default.
W3137683544 hasConceptScore W3137683544C126322002 @default.
W3137683544 hasConceptScore W3137683544C142424586 @default.
W3137683544 hasConceptScore W3137683544C143998085 @default.
W3137683544 hasConceptScore W3137683544C197934379 @default.